Himalaya Nutravedics IPO
IPO price, dates, financial performance, strengths, risks and offer details
₹2,40,000 / 2,400 shares
Bidding Dates22 Sept, 26 – 24 Sept, 26
Min Investment₹2,40,000
Lot Size1,200
Price Range₹100 – ₹106
IPO Timeline
IPO Offer Start22 Sept, 26
IPO Offer Ends24 Sept, 26
Allotment Finalisation25 Sept, 26
Refund Initiation28 Sept, 26
Listing of Shares29 Sept, 26
Strengths
Integrated in-house manufacturingThe company operates an integrated production facility capable of manufacturing medicated oils, softgel capsules, hardgel capsules, tablets and liquid oral formulations. This allows multiple dosage formats to be developed and produced without depending entirely on external manufacturers.
Repeat prescriptions and focused marketingThe company's formulations have generated repeat prescriptions through scientific product detailing, CME programmes and medical camps. Marketing expenditure represented only 4.16% of total revenue in FY2025-26, supporting cost control.
Established repeat customer baseThe top ten customers contributed 81.24% of revenue from operations in FY2025-26, equivalent to ₹3,498.75 lakhs. The company attributes repeat engagements to supply reliability and acceptance of its products.
Rapid expansion across statesSince beginning operations in September 2022, the company has expanded its branded business into 17 states in roughly three years. This expansion aligns with the projected growth of India's nutraceuticals market, estimated at a CAGR of 13.6%–15.9% through 2030.
Broad therapeutic portfolioThe product range covers categories including gut health, cardiac and metabolic wellness, diabetes care, pain management, immunity and infertility. This breadth provides opportunities to serve different prescribing requirements and support cross-selling.
Risks
High customer concentrationThe ten largest customers contributed 81.24%, 86.97% and 84.19% of revenue from operations in Fiscals 2026, 2025 and 2024 respectively. The company does not have long-term customer contracts, leaving revenue exposed to cancellations, delays and reduced orders.
Heavy dependence on Ayurvedic productsAyurvedic products represented 94.57%, 92.09% and 79.27% of revenue from operations in Fiscals 2026, 2025 and 2024 respectively. Lower demand, regulatory intervention or stronger competition in this segment could materially affect business and cash flows.
Persistent negative operating cash flowOperating cash flow was negative at ₹383.44 lakhs in FY2026, ₹139.11 lakhs in FY2025 and ₹55.10 lakhs in FY2024. Elevated working capital requirements, including inventory and receivables, have contributed to the cash pressure.
Expiry of tax holidayThe company currently benefits from a Section 80-IAC income tax holiday covering Fiscals 2025, 2026 and 2027. After the benefit expires, the applicable tax burden is expected to rise to approximately 25% plus surcharge and cess, which the company estimates could reduce PAT by around 28% of corresponding PBT.
Single leased manufacturing siteThe company operates from one leased facility in Hyderabad, Telangana. Natural disasters, political disruptions or other regional events could interrupt production, while existing insurance may not necessarily cover the full extent of potential losses.
Pending trademark oppositionTrademark applications 5640519 and 5640476 are subject to opposition proceedings before the Registrar of Trademarks. An adverse outcome could require changes to the company's corporate logo or word mark and potentially affect brand recognition across its 100-plus product portfolio.
Supplier concentrationThe ten largest suppliers accounted for 94.30%, 94.84% and 97.32% of purchases in Fiscals 2026, 2025 and 2024 respectively. With no long-term supplier contracts, losing a key supplier or facing supply disruption could affect production, financial performance and cash flows.
Regulatory and product liability exposureThe company operates under evolving requirements administered by FSSAI and the Ministry of AYUSH, with periodic inspections and audits of its manufacturing facility. Non-compliance could lead to recalls, suspension or cancellation of approvals, penalties and reputational damage. Product liability claims may also arise.
Rising working capital needsWorking capital requirements increased to ₹1,748.53 lakhs in FY2026 from ₹287.25 lakhs in FY2024. Trade receivables reached ₹1,058.69 lakhs, or 24.58% of FY2026 revenue. Payment delays or defaults combined with limited financing availability could put further pressure on operations.
Dependence on promoters and key personnelThe business relies significantly on promoter experience and continued involvement for strategy, business development and operational decisions. Some key managerial personnel have been associated with the company for less than one year and do not have listed-company experience, creating potential operational and compliance risks.
Objectives
A portion of the Net Proceeds is proposed to fund working capital requirements in the ordinary course of business and support the company's planned expansion into Direct-to-Consumer (D2C) channels, including inventory, receivable cycles and fulfilment needs.
Part of the Net Proceeds is intended for branding, digital marketing and sales expansion. Planned activities include advertising through e-commerce and quick-commerce platforms, building a proprietary D2C website and running performance marketing campaigns for customer acquisition.
The remaining Net Proceeds are proposed for general corporate purposes, including strategic initiatives, expansion of marketing capabilities and network, brand development, business exigencies, employee salaries and routine operating expenses, subject to applicable regulatory limits.
Yearly Financial Results
Standalone
| Annual Financials | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 14.43 | 21.00 | 43.07 |
| Expenses | 13.83 | 18.75 | 35.64 |
| Other Income | 0.00 | 0.00 | 0.05 |
| Total Revenue | 14.43 | 21.00 | 43.12 |
| Profit Before Tax | 0.59 | 2.25 | 7.48 |
| Net Profit | 0.43 | 2.23 | 7.39 |
Above figures are in Rs. Crores
Balance Sheet
Standalone
| Balance Sheet | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Total Assets | 6.09 | 10.82 | 24.42 |
| Current Assets | 4.58 | 9.12 | 21.70 |
| Fixed Assets | 1.52 | 1.69 | 2.72 |
| Total Equity & Liabilities | 6.09 | 10.82 | 24.42 |
| Total Liabilities | 4.74 | 4.06 | 8.04 |
| Current Liabilities | 4.07 | 3.42 | 7.90 |
| Non Current Liabilities | 0.67 | 0.64 | 0.14 |
| Total Equity | 1.36 | 6.76 | 16.38 |
Above figures are in Rs. Crores
Cash Flow
Standalone
| Cash Flow | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Net Cash Flow | 0.19 | -0.18 | 1.38 |
| Investing Activities | -1.10 | -0.23 | -0.06 |
| Operating Activities | -0.55 | -1.39 | -3.83 |
| Financing Activities | 1.84 | 1.44 | 5.27 |
Above figures are in Rs. Crores
About Himalaya Nutravedics
Himalaya Nutravedics India Limited is headquartered in Hyderabad and manufactures, markets and distributes Ayurvedic and nutraceutical formulations. Its hybrid model combines own-brand products, including classical and proprietary Ayurvedic formulations and nutraceutical supplements, with third-party contract manufacturing. The company operates a single WHO-GMP, ISO 9001:2015 and ISO 22000:2018 certified integrated facility in Cherlapally, Hyderabad, producing softgels, tablets, medicated oils, liquid orals and hardgel capsules. Revenue from operations increased from ₹1,442.56 lakhs in FY2024 to ₹4,306.75 lakhs in FY2026, while PAT reached ₹738.97 lakhs. The branded business represented 51.14% of FY2026 revenue. The company follows a doctor-focused offline distribution model across 17 states, supported by around 58 sales personnel and a stockist-led network, with plans for nationwide expansion, portfolio diversification and potential export markets.
Discussion
Share your thoughts, ask questions, or discuss this IPO with other investors.
No comments yet. Be the first to share your thoughts!
Leave a Comment